Original Research

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling

Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M

Patient Preference and Adherence 2020, 14:2201-2214

Published Date: 5 November 2020